Start free trial

TRUE, BUTLab Not Field

No mice, no patients yet.

“New AI unlocks a cancer treatment, and scientists are stunned”

Headline trending on r/artificial, October 2026, on UCLA's MAESTRO study in Advanced Science

Recorded 23 October 2026. Our ruling means: literally true, materially misleading.

Read the story →

Receipts pack

The evidence file for this verdict

11 receipts: 4 support the claim, 2 contradict it, 5 add context. 3 figures on the record, 3 traced to a quoted receipt.

The receipts

Each source, the line we quote from it, its date and which way it cuts. Free to read and to cite.

  1. 1Supports the claimuclahealth.org ↗

    The researchers used the platform to evaluate 3,592 natural products for their potential to work with enzalutamide.

    Look up an archived copy ↗

  2. 2Contextuclahealth.org ↗

    a drug originally discovered and developed at UCLA that is commonly used to treat advanced prostate cancer

    Look up an archived copy ↗

  3. 3Contextuclahealth.org ↗

    The system identified 150 high-confidence candidates for testing in 3D prostate cancer spheroids.

    Look up an archived copy ↗

  4. 4Contextuclahealth.org ↗

    Of the 150 compounds tested, 23 showed evidence of synergy with enzalutamide

    Look up an archived copy ↗

  5. 5Supports the claimuclahealth.org ↗

    Further testing identified berberine, a naturally occurring compound found in several plants, as a particularly promising candidate.

    Look up an archived copy ↗

  6. 6Contradicts the claimuclahealth.org ↗

    The researchers plan to further evaluate the combination in patient-derived tumor models and animal studies.

    Look up an archived copy ↗

  7. 7Supports the claimuclahealth.org ↗

    MAESTRO could substantially accelerate this process.

    Look up an archived copy ↗

  8. 8Supports the claimuclahealth.org ↗

    berberine and enzalutamide showed consistent synergy across four prostate cancer models with different mechanisms of treatment resistance

    Look up an archived copy ↗

  9. 9Contradicts the claimebi.ac.uk ↗

    berberine-enzalutamide as an in vitro combination hit that re-sensitized resistant prostate cancer cells to AR blockade

    Look up an archived copy ↗

  10. 10Contextebi.ac.uk ↗

    can prioritize and experimentally evaluate drug-combination hypotheses at an early stage of discovery.

    Look up an archived copy ↗

  11. 11Contexteutils.ncbi.nlm.nih.gov ↗

    This work introduces a hybrid in silico and in vitro lead discovery platform

    Look up an archived copy ↗

Members' extras

What each receipt proves, and what would change our mind.

  • What each receipt above proves, in our words
  • The figures table, each number traced to the receipt that states it
  • The trick behind the claim, explained, with the guide to spotting it
  • What would change our verdict
  • Our call on the record, with its due date

The verdict, the opening and every receipt above stay free. Membership adds our analysis to the evidence file for every checked story.

See Membership →Already a member? Sign in →

First membership: 30 days free, then A$89 a year. One introductory trial per customer. Card required; renews annually until cancelled. Cancel before the trial ends to avoid the first charge.